EuCorVac-19
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[1][2][3][4][5]
References[edit]
- ^ "Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. Retrieved 20 March 2021.
- ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. Retrieved 17 April 2021.
- ^ Moon-hee, Choi (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine 'EuCOVAC-19'". Business Korea. Retrieved 17 April 2021.
- ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. Retrieved 17 April 2021.
- ^ "Firm looks to build vaccine manufacturing plant in PH". ABS-CBN News. 12 April 2021. Retrieved 17 April 2021.
 |
Scholia has a profile for EuCorVac-19 (Q106672023). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |